Login Register Cart 0
Review Article

抗VEGF和视网膜营养不良

卷 21, 期 12, 2020

页: [1201 - 1207] 页: 7

弟呕挨: 10.2174/1389450121666200428103334

价格: $65

摘要

基于抗血管内皮生长因子(anti-vascular endothelial growth factor, VEGF)分子的治疗方法可用于治疗视网膜营养不良的两种重要并发症:脉络膜新生血管和黄斑水肿。视网膜营养不良的黄斑病变在患者年纪尚轻且已经受到功能限制的影响时，会导致视力进一步恶化。该研究报告了抗VEGF治疗几种亚型的视网膜营养不良的效果，批判性地讨论了优点和局限性。

关键词: 脉络膜新生血管，黄斑水肿，色素性视网膜炎，最佳黄斑卵黄样营养不良，黄斑变性疾病，营养不良，抗VEGF

« Previous Next »
图形摘要

[1]
Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2000; 238(9): 760-4.
[http://dx.doi.org/10.1007/s004170000186] [PMID: 11045344]
[2]
Battaglia Parodi M, Iacono P, Bandello F. Antivascular endothelial growth factor in hereditary dystrophies. Dev Ophthalmol 2010; 46: 107-10.
[http://dx.doi.org/10.1159/000320013] [PMID: 20703036]
[3]
Triolo G, Pierro L, Parodi MB, et al. Spectral domain optical coherence tomography findings in patients with retinitis pigmentosa. Ophthalmic Res 2013; 50(3): 160-4.
[http://dx.doi.org/10.1159/000351681] [PMID: 23989166]
[4]
Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 1999; 128(2): 185-91.
[http://dx.doi.org/10.1016/S0002-9394(99)00100-2] [PMID: 10458174]
[5]
Iwakiri R, Okinami S, Hirata A. Two cases of retinitis pigmentosa associated with choroidal neovascularization. Nippon Ganka Gakkai Zasshi 2007; 111(8): 606-11.
[PMID: 17874536]
[6]
Cheng JY, Adrian KH. Photodynamic therapy for choroidal neovascularization in stargardt disease and retinitis pigmentosa. Retin Cases Brief Rep 2009; 3(4): 388-90.
[http://dx.doi.org/10.1097/ICB.0b013e31817f2e3f] [PMID: 25389856]
[7]
Battaglia Parodi M, De Benedetto U, Knutsson KA, et al. Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. J Ocul Pharmacol Ther 2012; 28(2): 202-4.
[http://dx.doi.org/10.1089/jop.2011.0140] [PMID: 22149640]
[8]
Miyata M, Oishi A, Oishi M, Hasegawa T, Ikeda HO, Tsujikawa A. Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report. BMC Ophthalmol 2018; 14: 18-248.
[http://dx.doi.org/10.1186/s12886-018-0914-z]
[9]
Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther 2009; 25(6): 545-50.
[http://dx.doi.org/10.1089/jop.2009.0089] [PMID: 20028262]
[10]
Yuzbasioglu E, Artunay O, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res 2009; 34(3): 231-7.
[http://dx.doi.org/10.1080/02713680802710692] [PMID: 19274531]
[11]
Moustafa GA, Moschos MM. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature. BMC Ophthalmol 2015; 15: 44.
[http://dx.doi.org/10.1186/s12886-015-0033-z] [PMID: 25925748]
[12]
Strong SA, Peto T, Bunce C, et al. Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa. Br J Ophthalmol 2020; 2: 10.
[http://dx.doi.org/10.1136/bjophthalmol-2019-315152]
[13]
Salom D, Diaz-Llopis M, García-Delpech S, Udaondo P, Sancho-Tello M, Romero FJ. Aqueous humor levels of vascular endothelial growth factor in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2008; 49(8): 3499-502.
[http://dx.doi.org/10.1167/iovs.07-1168] [PMID: 18326689]
[14]
Khan KN, Mahroo OA, Islam F, Webster AR, Moore AT, Michaelides M. Functional and anatomical outcomes of choroidal neovascularization complicating BEST1-related retinopathy. Retina 2017; 37(7): 1360-70.
[http://dx.doi.org/10.1097/IAE.0000000000001357] [PMID: 27764019]
[15]
Battaglia Parodi M, Iacono P, Romano F, Bandello F. Spectral domain optical coherence tomography features in different stages of stages of Best vitelliform macular dystrophy. Retina 2018; 38(5): 1041-6.
[http://dx.doi.org/10.1097/IAE.0000000000001634] [PMID: 28376040]
[16]
Battaglia Parodi M, Romano F, Cicinelli MV, et al. Retinal vascular impairment in best vitelliform macular dystrophy assessed by means of optical coherence tomography angiography. Am J Ophthalmol 2018; 187: 61-70.
[http://dx.doi.org/10.1016/j.ajo.2017.12.013] [PMID: 29288639]
[17]
Battaglia Parodi M, Casalino G, Iacono P, Introini U, Adamyan T, Bandello F. The expanding clinical spectrum of choroidal excavation in macular dystrophies. Retina 2018; 38(10): 2030-4.
[http://dx.doi.org/10.1097/IAE.0000000000001805] [PMID: 28800018]
[18]
Guduru A, Gupta A, Tyagi M, Jalali S, Chhablani J. Optical coherence tomography angiography characterisation of Best disease and associated choroidal neovascularisation. Br J Ophthalmol 2018; 102(4): 444-7.
[PMID: 28765145]
[19]
Shahzad R, Siddiqui MA. Choroidal neovascularization secondary to Best vitelliform macular dystrophy detected by optical coherence tomography angiography. J AAPOS 2017; 21(1): 68-70.
[http://dx.doi.org/10.1016/j.jaapos.2016.08.018] [PMID: 27867022]
[20]
Battaglia Parodi M, Romano F, Arigo A, et al. Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2020; 258(2): 297-301.
[http://dx.doi.org/10.1007/s00417-019-04454-4] [PMID: 31848692]
[21]
Padhi TR, Anderson BJ, Abbey AM, et al. Choroidal neovascular membrane in paediatric patients: clinical characteristics and outcomes. Br J Ophthalmol 2018; 102(9): 1232-7.
[http://dx.doi.org/10.1136/bjophthalmol-2017-310497] [PMID: 29217515]
[22]
Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997; 15(3): 236-46.
[http://dx.doi.org/10.1038/ng0397-236] [PMID: 9054934]
[23]
Koenekoop RK. The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review. Ophthalmic Genet 2003; 24(2): 75-80.
[http://dx.doi.org/10.1076/opge.24.2.75.13996] [PMID: 12789571]
[24]
Battaglia Parodi M. Eredodistrofie Corioretiniche. Rome: Verduci Editore 2002; pp. 21-60.
[25]
Lee W, Xie Y, Zernant J, et al. Complex inheritance of ABCA4 disease: four mutations in a family with multiple macular phenotypes. Hum Genet 2016; 135(1): 9-19.
[http://dx.doi.org/10.1007/s00439-015-1605-y] [PMID: 26527198]
[26]
Arrigo A, Grazioli A, Romano F, et al. Multimodal evaluation of central and peripheral alterations in Stargardt disease: a pilot study. Br J Ophthalmol 2019.bjophthalmol-2019-315148.
[http://dx.doi.org/10.1136/bjophthalmol-2019-315148] [PMID: 31748334]
[27]
Franceschetti A, François J. Fundus flavimaculatus. Arch Ophtalmol Rev Gen Ophtalmol 1965; 25(6): 505-30.
[PMID: 4221555]
[28]
Armstrong JD, Meyer D, Xu S, Elfervig JL. Long-term follow-up of Stargardt’s disease and fundus flavimaculatus. Ophthalmology 1998; 105(3): 448-57.
[http://dx.doi.org/10.1016/S0161-6420(98)93026-3] [PMID: 9499775]
[29]
Klein R, Lewis RA, Meyers SM, Myers FL. Subretinal neovascularization associated with fundus flavimaculatus. Arch Ophthalmol 1978; 96(11): 2054-7.
[http://dx.doi.org/10.1001/archopht.1978.03910060442009] [PMID: 718494]
[30]
Pawlak D, Souied E, Mimoun G, Papp-Pawlak M, Coscas G, Soubrane G. [Fundus flavimaculatus and choroidal neovascularization. J Fr Ophtalmol 2006; 29(2): 188-94.
[http://dx.doi.org/10.1016/S0181-5512(06)73770-6] [PMID: 16523163]
[31]
Quijano C, Querques G, Massamba N, Soubrane G, Souied EH. Type 3 choroidal neovascularization associated with fundus flavimaculatus. Ophthalmic Res 2009; 42(3): 152-4.
[http://dx.doi.org/10.1159/000229030] [PMID: 19628956]
[32]
Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology 2003; 110(6): 1151-8.
[http://dx.doi.org/10.1016/S0161-6420(03)00333-6] [PMID: 12799240]
[33]
Valmaggia C, Niederberger H, Helbig H. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus. Retina 2002; 22(1): 111-3.
[http://dx.doi.org/10.1097/00006982-200202000-00022] [PMID: 11884891]
[34]
Souied EH, Pawlak D, Algan M, Sayag D, Coscas G, Soubrane G. Photodynamic therapy for choroidal neovascularization on late-onset fundus flavimaculatus. Am J Ophthalmol 2005; 140(2): 312-4.
[http://dx.doi.org/10.1016/j.ajo.2005.01.024] [PMID: 16086955]
[35]
Japiassú RM, Moura Brasil OF, Maia HS, Maia AS, Brasil OM. Photodynamic therapy for bilateral and simultaneous choroidal neovascularization in stargardt disease. Retin Cases Brief Rep 2008; 2(1): 9-11.
[http://dx.doi.org/10.1097/ICB.0b013e3180467837] [PMID: 25389604]
[36]
Kim HH, Carvounis PE, Albini TA, Holz ER, Mieler WF. Photodynamic therapy for bilateral subfoveal choroidal neovascularization complicating stargardt macular dystrophy. Retin Cases Brief Rep 2008; 2(1): 6-8.
[http://dx.doi.org/10.1097/ICB.0b013e318033907f] [PMID: 25389603]
[37]
Braun B, Schneider U, Hasler P, Prünte C. Combination therapy of PDT and triamcinolone in CNV associated with fundus flavimaculatus. Klin Monatsbl Augenheilkd 2007; 224(4): 353-5.
[http://dx.doi.org/10.1055/s-2007-962838] [PMID: 17458813]
[38]
Querques G, Bocco MC, Soubrane G, Souied EH. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease. Graefes Arch Clin Exp Ophthalmol 2008; 246(2): 319-21.
[http://dx.doi.org/10.1007/s00417-007-0689-z] [PMID: 17934751]
[39]
Tejerina AN, García-Pous M, Pozos EP, Esteban MC, Boronat JM. Ranibizumab for choroidal neovascularization in fundus flavimaculatus. Retin Cases Brief Rep 2008; 2(3): 250-2.
[http://dx.doi.org/10.1097/ICB.0b013e31816b31d1] [PMID: 25390102]
[40]
Koh V, Naing T, Chee C. Fundus flavimaculatus and choroidal neovascularization in a young patient with normal electroretinography: case report. Can J Ophthalmol 2012; 47(3): e3-5.
[http://dx.doi.org/10.1016/j.jcjo.2012.03.003] [PMID: 22687319]
[41]
Battaglia Parodi M, Munk MR, Iacono P, Bandello F. Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. Br J Ophthalmol 2015; 99(9): 1268-70.
[http://dx.doi.org/10.1136/bjophthalmol-2014-305783] [PMID: 25740804]
[42]
Roy R, Kumar A, Ghosh S, Lobo A, Agarwal P. All that glitters are not flecks: inflammatory choroidal neovascularization in fundus flavimaculatus. Ocul Immunol Inflamm 2015; 23(2): 188-90.
[http://dx.doi.org/10.3109/09273948.2013.873810] [PMID: 24484270]
[43]
Radu RA, Hu J, Yuan Q, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem 2011; 286(21): 18593-601.
[http://dx.doi.org/10.1074/jbc.M110.191866] [PMID: 21464132]
[44]
Cicinelli MV, Battista M, Starace V, Battaglia Parodi M, Bandello F. Monitoring and Management of the Patient with Stargardt Disease. Clin Optom (Auckl) 2019; 11: 151-65.
[http://dx.doi.org/10.2147/OPTO.S226595] [PMID: 31819694]
[45]
Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. 4th ed. St. Louis: CV Mosby 1997; pp. 314-25.
[46]
Francis PJ, Schultz DW, Gregory AM, et al. Genetic and phenotypic heterogeneity in pattern dystrophy. Br J Ophthalmol 2005; 89(9): 1115-9.
[http://dx.doi.org/10.1136/bjo.2004.062695] [PMID: 16113362]
[47]
Marmor MF, Byers B. Pattern dystrophy of the retinal pigment epithelium. Am J Ophthalmol 1976; 13: 112-6.
[PMID: 8794711]
[48]
Taillanter-Francoz N, Remy C, Bonnet M, Baserer T. Choroidal neovessels associated with reticular dystrophy of the pigment epithelium (case report). Bull Soc Ophtalmol Fr 1981; 81(4-5): 539-41.
[PMID: 6167375]
[49]
Marano F, Deutman AF, Pinckers AJ, Aandekerk AL, Rijneveld WJ. Reticular dystrophy of the retinal pigment epithelium and choroidal neovascularization. A fluorescein and ICGV study. Acta Ophthalmol Scand 1997; 75(1): 22-7.
[http://dx.doi.org/10.1111/j.1600-0420.1997.tb00243.x] [PMID: 9088395]
[50]
Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina 2003; 23(2): 171-6.
[http://dx.doi.org/10.1097/00006982-200304000-00006] [PMID: 12707595]
[51]
Parodi MB, Liberali T, Pedio M, et al. Photodynamic therapy of subfoveal choroidal neovascularization secondary to reticular pattern dystrophy: three-year results of an uncontrolled, prospective case series. Am J Ophthalmol 2006; 141(6): 1152-4.
[http://dx.doi.org/10.1016/j.ajo.2006.01.038] [PMID: 16765697]
[52]
Battaglia Parodi M. Choroidal neovascularization in fundus pulverulentus. Acta Ophthalmol Scand 2002; 80(5): 559-60.
[http://dx.doi.org/10.1034/j.1600-0420.2002.800521.x] [PMID: 12390174]
[53]
Parodi MB, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 2010; 51(9): 4358-61.
[http://dx.doi.org/10.1167/iovs.10-5237] [PMID: 20375343]
[54]
Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. Retina 2013; 33(3): 513-21.
[http://dx.doi.org/10.1097/IAE.0b013e3182753adb] [PMID: 23400081]
[55]
Empeslidis T, Vardarinos A, Deane J, Banerjee S. Intravitreal ranibizumab in the treatment of butterfly-shaped pattern dystrophy associated with choroidal neovascularization: a case report. Case Rep Ophthalmol 2012; 3(1): 77-82.
[http://dx.doi.org/10.1159/000336987] [PMID: 22529806]
[56]
Vaclavik V, Tran HV, Gaillard MC, Schorderet DF, Munier FL. Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin/RDS gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-VEGF (ranibizumab) intravitreal injections. Retina 2012; 32(9): 1942-9.
[http://dx.doi.org/10.1097/IAE.0b013e31824b32e4] [PMID: 22466463]
[57]
Tiosano L, Jaouni T, Averbukh E, Grunin M, Banin E, Chowers I. Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol 2014; 24(6): 890-6.
[http://dx.doi.org/10.5301/ejo.5000486] [PMID: 24846624]
[58]
Battaglia Parodi M, Romano F, Marchese A, et al. Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2019; 257(2): 273-8.
[http://dx.doi.org/10.1007/s00417-018-4190-7] [PMID: 30470876]
[59]
Bietti G. Ueber familiaeres vorkommen von ‘retinitis punctata albescens’ (verbunden mit ‘dystrophia marginalis cristallinea corneae’), glitzern des glaskoerpers und anderen degenerativen augenveraenderungen. Klin Monatsbl Augenheilkd 1939; 99: 737-57.
[60]
Li A, Jiao X, Munier FL, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet 2004; 74(5): 817-26.
[http://dx.doi.org/10.1086/383228] [PMID: 15042513]
[61]
Li Q, Li Y, Zhang X, et al. Utilization of fundus autofluorescence, spectral domain optical coherence tomography, and enhanced depth imaging in the characterization of Bietti crystalline dystrophy in different stages. Retina 2015; 35: 2074-84.
[http://dx.doi.org/10.1097/IAE.0000000000000592]
[62]
Le Tien V, Atmani K, Querques G, Massamba N, Souied EH. Ranibizumab for subfoveal choroidal neovascularization in Bietti crystalline retinopathy. Eye (Lond) 2010; 24(11): 1728-9.
[http://dx.doi.org/10.1038/eye.2010.116] [PMID: 20798693]
[63]
Gupta B, Parvizi S, Mohamed MD. Bietti crystalline dystrophy and choroidal neovascularisation. Int Ophthalmol 2011; 31(1): 59-61.
[http://dx.doi.org/10.1007/s10792-010-9406-8] [PMID: 20972604]
[64]
Atmaca LS, Muftuoglu O, Atmaca-Sonmez P. Peripapillary choroidal neovascularization in Bietti crystalline retinopathy. Eye (Lond) 2007; 21(6): 839-42.
[http://dx.doi.org/10.1038/sj.eye.6702673] [PMID: 17173010]
[65]
Nachiappan K, Krishnan T, Madhavan J. Ranibizumab for choroidal neovascular membrane in a rare case of Bietti’s crystalline dystrophy: a case report. Indian J Ophthalmol 2012; 60(3): 207-9.
[http://dx.doi.org/10.4103/0301-4738.95873] [PMID: 22569382]
[66]
Yin X, Yang L, Chen N, et al. Identification of CYP4V2 mutation in 36 Chinese families with Bietti crystalline corneoretinal dystrophy. Exp Eye Res 2016; 146: 154-62.
[http://dx.doi.org/10.1016/j.exer.2016.03.007] [PMID: 26971461]
[67]
Mamatha G, Umashankar V, Kasinathan N, et al. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization. Mol Vis 2011; 17: 1970-7.
[PMID: 21850171]
[68]
Inanc M, Tekin K, Teke MY. Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab. Int Ophthalmol 2018; 38(3): 1351-5.
[http://dx.doi.org/10.1007/s10792-017-0579-2] [PMID: 28560651]
[69]
Gulkilik G, Erdur SK, Eliacik M, et al. A case of cone dystrophy associated with choroidal neovascularization. Retin Cases Brief Rep 2018; 12(2): 111-4.
[http://dx.doi.org/10.1097/ICB.0000000000000437] [PMID: 27685498]
[70]
Chatziralli I, Theodossiadis G, Emfietzoglou I, Theodossiadis P. Intravitreal ranibizumab for choroidal neovascularization secondary to gyrate atrophy in a young patient: a multimodal imaging analysis. Eur J Ophthalmol 2015; 25(6): e119-22.
[http://dx.doi.org/10.5301/ejo.5000660] [PMID: 26419008]
[71]
Marano F, Deutman AF, Pinckers AJ, Aandekerk AL. Gyrate atrophy and choroidal neovascularization. Arch Ophthalmol 1996; 114(10): 1295.
[http://dx.doi.org/10.1001/archopht.1996.01100140495035] [PMID: 8859105]
[72]
Campos-Pavón J, Torres-Peña JL. Choroidal neovascularization secondary to choroideremia. Arch Soc Esp Oftalmol 2015; 90(6): 289-91.
[http://dx.doi.org/10.1016/j.oftal.2014.03.012] [PMID: 25433417]
[73]
Palejwala NV, Lauer AK, Weleber RG. Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab. Clin Ophthalmol 2014; 8: 1675-9.
[http://dx.doi.org/10.2147/OPTH.S68243] [PMID: 25214760]
[74]
Endo K, Yuzawa M, Ohba N. Choroideremia associated with subretinal neovascular membrane. Acta Ophthalmol Scand 2000; 78(4): 483-6.
[http://dx.doi.org/10.1034/j.1600-0420.2000.078004483.x] [PMID: 10990059]
[75]
Robinson D, Tiedeman J. Choroideremia associated with a subretinal neovascular membrane. Case report. Retina 1987; 7(2): 70-4.
[http://dx.doi.org/10.1097/00006982-198700720-00002] [PMID: 2442805]
[76]
Bertoli F, Pignatto S, Rizzetto F, Lanzetta PA. 5-Year-Old Case of Choroidal Neovascularization in Enhanced S-Cone Syndrome Treated with Ranibizumab. Case Rep Ophthalmol 2018; 9(3): 510-5.
[http://dx.doi.org/10.1159/000495743] [PMID: 30687072]
[77]
Broadhead GK, Grigg JR, McCluskey P, Korsakova M, Chang AA. Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome. Doc Ophthalmol 2016; 133(2): 139-43.
[http://dx.doi.org/10.1007/s10633-016-9555-9] [PMID: 27424008]
[78]
Ranchod TM, Faia LJ, Drenser KA. Peripapillary choroidal neovascularization in congenital retinoschisis. Retin Cases Brief Rep 2011; 5(4): 336-8.
[http://dx.doi.org/10.1097/ICB.0b013e3181ff0960] [PMID: 25390429]

Rights & Permissions Print Cite
Article Metrics
39
4
1
© 2024 Bentham Science Publishers | Privacy Policy